Related Experiment Video

Updated: Sep 21, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

[Gemicitabine in the treatment of epithelial ovarian cancer]

Patricia Pautier1, Maya Gutierrez, Catherine Lhomme

  • 1Service de gynécologie médicale, Département de médecine adulte, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif. pautier@igr.fr

Bulletin Du Cancer
|November 27, 2002
PubMed

Insights

Gemcitabine shows promise in treating ovarian cancer, particularly in recurrent or platinum-refractory cases. Combination therapy with platinum compounds yielded encouraging response rates, supporting further clinical trials.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Ovarian cancer, despite being chemosensitive, has a low cure rate, with most patients experiencing disease recurrence.
  • Gemcitabine, an antimetabolite, demonstrated preclinical activity, leading to its investigation in clinical trials.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of gemcitabine as a monotherapy and in combination with platinum compounds for ovarian cancer treatment.

Main Methods:

  • Phase II trials assessed gemcitabine monotherapy in refractory or platinum-refractory ovarian cancer.
  • Subsequent trials explored combinations of gemcitabine with platinum compounds.

Main Results:

  • Gemcitabine monotherapy achieved response rates of 11%–22% in resistant ovarian cancer.
  • Combination therapy with platinum compounds resulted in significantly higher response rates, ranging from 61% to 67%.

Conclusions:

  • Gemcitabine is an active agent in treating refractory recurrent ovarian cancer.
  • Combination therapy with platinum compounds demonstrates encouraging efficacy, warranting further investigation in first-line treatment settings.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum05:42

An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum

Published on: January 26, 2024

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...